Opus Genetics Inc
NASDAQ:IRD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Opus Genetics Inc
Cash from Financing Activities
Opus Genetics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Opus Genetics Inc
NASDAQ:IRD
|
Cash from Financing Activities
$50m
|
CAGR 3-Years
136%
|
CAGR 5-Years
19%
|
CAGR 10-Years
20%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$10.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Opus Genetics Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See Also
What is Opus Genetics Inc's Cash from Financing Activities?
Cash from Financing Activities
50m
USD
Based on the financial report for Dec 31, 2025, Opus Genetics Inc's Cash from Financing Activities amounts to 50m USD.
What is Opus Genetics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
20%
Over the last year, the Cash from Financing Activities growth was 1 095%. The average annual Cash from Financing Activities growth rates for Opus Genetics Inc have been 136% over the past three years , 19% over the past five years , and 20% over the past ten years .
